These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34326124)

  • 1. Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.
    Woff E; Salvatore L; Marmorino F; Genovesi D; Critchi G; Guiot T; Ameye L; Sclafani F; Hendlisz A; Flamen P
    J Nucl Med; 2022 Apr; 63(4):549-555. PubMed ID: 34326124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
    Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
    J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining
    Woff E; Kehagias P; Vandeputte C; Ameye L; Guiot T; Paesmans M; Hendlisz A; Flamen P
    J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics analysis of pre-treatment [
    van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting tumor response and outcome of second-look surgery with
    Aide N; Fauchille P; Coquan E; Ferron G; Combe P; Meunier J; Alexandre J; Berton D; Leary A; De Rauglaudre G; Bonichon N; Pujade Lauraine E; Joly F
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1998-2008. PubMed ID: 33221969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic tumor burden quantified on [
    Lapa P; Oliveiros B; Marques M; Isidoro J; Alves FC; Costa JMN; Costa G; de Lima JP
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2169-2178. PubMed ID: 28785842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of the Pace of Tumor Progression as Assessed by Serial
    Camera S; Akin Telli T; Woff E; Vandeputte C; Kehagias P; Guiot T; Critchi G; Wissam Y; Bregni G; Trevisi E; Pretta A; Senti C; Leduc S; Gkolfakis P; Hoerner F; Rothé F; Sclafani F; Flamen P; Deleporte A; Hendlisz A
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of volume-based parameters using
    Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
    Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma.
    van Sluis J; de Heer EC; Boellaard M; Jalving M; Brouwers AH; Boellaard R
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1498-1510. PubMed ID: 33099667
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.
    Hendlisz A; Deleporte A; Delaunoit T; Maréchal R; Peeters M; Holbrechts S; Van den Eynde M; Houbiers G; Filleul B; Van Laethem JL; Ceyssens S; Barbuto AM; Lhommel R; Demolin G; Garcia C; El Mansy H; Ameye L; Moreau M; Guiot T; Paesmans M; Piccart M; Flamen P
    PLoS One; 2015; 10(9):e0138341. PubMed ID: 26421426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study.
    Frings V; van Velden FH; Velasquez LM; Hayes W; van de Ven PM; Hoekstra OS; Boellaard R
    Radiology; 2014 Nov; 273(2):539-48. PubMed ID: 24865311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of
    Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
    Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    van Helden EJ; Hoekstra OS; Boellaard R; Roth C; Mulder ER; Verheul HM; Menke-van der Houven van Oordt CW
    PLoS One; 2016; 11(5):e0155178. PubMed ID: 27196139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
    Lee J; Sato MM; Coel MN; Lee KH; Kwee SA
    J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.
    Cardone C; De Stefano A; Rosati G; Cassata A; Silvestro L; Borrelli M; Di Gennaro E; Romano C; Nappi A; Zanaletti N; Foschini F; Casaretti R; Tatangelo F; Lastoria S; Raddi M; Bilancia D; Granata V; Setola S; Petrillo A; Vitagliano C; Gargiulo P; Arenare L; Febbraro A; Martinelli E; Ciardiello F; Delrio P; Budillon A; Piccirillo MC; Avallone A
    ESMO Open; 2023 Feb; 8(1):100748. PubMed ID: 36603521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with
    Wibmer AG; Morris MJ; Gonen M; Zheng J; Hricak H; Larson S; Scher HI; Vargas HA
    J Nucl Med; 2021 Aug; 62(8):1050-1056. PubMed ID: 33419944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.